Foreclosures | Mortgages | Financing
Better to buy a hub or stand-alone devices? Sign up with the cable company? Get a Wi-Fi dog camera? Find answers to these and other questions in our connected-home guide of picks and expert advice …read more
From:: DIY this old house
Alkermes PLC shares ticked higher in the extended session Monday after the biotech company said the Food and Drug Adminstration approved its schizophrenia treatment Aristada. Alkermes shares rose 6.5% to $63.63. The company said the approval was based on data from a late-stage clinical study showing Aristada significantly reduced signs and symptoms of schizophrenia in patients after 12 weeks.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
Houston-based PLx Pharma Inc. on Monday filed for an initial public offering, seeking to sell up to $20 million worth of shares. The specialty pharmaceutical company focuses on delivery systems for safer, more effective oral drugs for cardiovascular disease, pain, and inflammation. The U.S. Food and Drug Administration has approved PLx’s lead product, a formulation of aspirin that reduces some of the drug’s side effects. The company said it plans to list on the Nasdaq under the symbol PLXP. PLx has lost 14 cents a share through June, and said it had a working capital deficit of about $203,000 and cash and cash equivalents of approximately $580,000. “As a result, our independent registered public accounting firm has noted that our recurring losses from operations and insufficient working capital raise substantial doubt regarding our ability to continue as a going concern without raising additional capital such as via this offering,” the company said in a filing.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
Haemonetics Corp. shares dropped in the extended session Monday after the company cut its outlook for the year. Haemonetics shares fell 12% to $29.29. The company, which specializes in blood-component collection and transfusion devices and services, cut its full-year forecast earnings range to $1.65 and $1.75 a share, from a previous range of $1.98 and $2.08 a share, on revenue of $910 million to $920 million. Analysts surveyed by FactSet had forecast $2.02 a share on revenue of $946.8 million.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
The Container Store Group Inc. said Monday that second quarter 2015 earnings per share were 6 cents for the period ending Aug. 29, down from 14 cents for the same period in 2014. Net sales for the quarter were $195.5 million, up from $193.2 million. Both figures missed Factset consensus estimates of 7 cents per share and $197.7 million in sales. Same-store sales were up 0.1% compared to the same period in 2014. The FactSet consensus was a decline of 0.7%. Net income for the quarter was $2.67 million down from $6.96 million the previous year. The company narrowed its fiscal 2015 same-store sales outlook to between -1% and 0% from -2% and 0%. The company is maintaining its net earnings per share outlook of between 30 cents and 38 cents per share. The Container Store stock is down 8.6% for the the past three months. The S&P is down 4.3% for the same period. Container Store stock is down 4.4% in after hours trading.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
Despite a growing economy, a new survey has found that the financial pressures of student debt, persistent confusion about the mortgage process and a continuing nationwide marriage rate decline are important factors combining to slow the housing market. The third annual America at Home survey from NeighborWorks America, found that student loan debt continues to […] …read more
From:: Finance and Economy
(TNS)—September hiring fell well short of consensus expectations and previous economic growth was less robust than thought, new Labor Department statistics say in a dismal monthly report that painted a picture of an economy in downshift mode. Employers added a disappointing 142,000 jobs in September, the Labor Department says Friday, and added just 136,000 jobs […] …read more
From:: Finance and Economy
Arena Pharmaceuticals Inc. shares rose in the extended session Monday following an announcement by the company its chief executive was retiring. Arena shares advanced 5.1% to $2.26. The drug developer said co-founder Jack Lief was retiring as president and CEO, and that Harry Hixson will serve as interim CEO. Arena said it will initiate a search for a new CEO immediately.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
Shares of DuPont jumped more than 4% in after-hours trade on Monday after the company reduced its full-year outlook and announced the retirement of long-time CEO Ellen Kullman, effective Oct. 16. The company said board member Edward Breen will serve as interim CEO until a full-time replacement is found. The company lowered its full-year earnings per share estimate to $2.75 from $3.10 previously, which it blamed on a strengthening U.S. dollar, as well as increased competition and macroeconomic issues in Brazil. Analysts on Wall Street are forecasting fiscal 2015 earnings per share of $3.19.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
General Mills Inc. said Monday it is voluntarily recalling several days of production of its Cheerios and Honey Nut Cheerios cereal produced at its Lodi, California facility on certain dates in July because they contain wheat, a known but undeclared allergen. The wheat was introduced in an isolated incident in which wheat flour was inadvertently added to the gluten-free oat flour system, the food company said in a statement. “Products containing wheat can cause illness or severe reactions for individuals with wheat allergies or celiac disease,” said the statement. Consumers seeking further information can call 1-800-775-8370.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News